375 related articles for article (PubMed ID: 30935795)
1. Selective degradation of CDK6 by a palbociclib based PROTAC.
Rana S; Bendjennat M; Kour S; King HM; Kizhake S; Zahid M; Natarajan A
Bioorg Med Chem Lett; 2019 Jun; 29(11):1375-1379. PubMed ID: 30935795
[TBL] [Abstract][Full Text] [Related]
2. Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.
Su S; Yang Z; Gao H; Yang H; Zhu S; An Z; Wang J; Li Q; Chandarlapaty S; Deng H; Wu W; Rao Y
J Med Chem; 2019 Aug; 62(16):7575-7582. PubMed ID: 31330105
[TBL] [Abstract][Full Text] [Related]
3. PROTAC-mediated CDK degradation differentially impacts cancer cell cycles due to heterogeneity in kinase dependencies.
Kumarasamy V; Gao Z; Zhao B; Jiang B; Rubin SM; Burgess K; Witkiewicz AK; Knudsen ES
Br J Cancer; 2023 Oct; 129(8):1238-1250. PubMed ID: 37626264
[TBL] [Abstract][Full Text] [Related]
4. Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib.
Poratti M; Marzaro G
Eur J Med Chem; 2019 Jun; 172():143-153. PubMed ID: 30978559
[TBL] [Abstract][Full Text] [Related]
5. Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6.
Jiang B; Wang ES; Donovan KA; Liang Y; Fischer ES; Zhang T; Gray NS
Angew Chem Int Ed Engl; 2019 May; 58(19):6321-6326. PubMed ID: 30802347
[TBL] [Abstract][Full Text] [Related]
6. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
[TBL] [Abstract][Full Text] [Related]
7. Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer.
Chen F; Liu C; Zhang J; Xu W; Zhang Y
Anticancer Agents Med Chem; 2018; 18(9):1241-1251. PubMed ID: 28403773
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs.
De Dominici M; Porazzi P; Xiao Y; Chao A; Tang HY; Kumar G; Fortina P; Spinelli O; Rambaldi A; Peterson LF; Petruk S; Barletta C; Mazo A; Cingolani G; Salvino JM; Calabretta B
Blood; 2020 Apr; 135(18):1560-1573. PubMed ID: 32040545
[TBL] [Abstract][Full Text] [Related]
9. Chemoproteomic Evaluation of Target Engagement by the Cyclin-Dependent Kinase 4 and 6 Inhibitor Palbociclib Correlates with Cancer Cell Response.
Nomanbhoy TK; Sharma G; Brown H; Wu J; Aban A; Vogeti S; Alemayehu S; Sykes M; Rosenblum JS; Kozarich JW
Biochemistry; 2016 Sep; 55(38):5434-41. PubMed ID: 27571378
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Biological Evaluation of Novel
Song X; Gan Q; Zhang X; Zhang J
Mol Pharm; 2019 Oct; 16(10):4213-4222. PubMed ID: 31424939
[TBL] [Abstract][Full Text] [Related]
11. Preparation and evaluation of
Gan Q; Song X; Zhang X; Zhang J
Eur J Med Chem; 2020 Feb; 188():112032. PubMed ID: 31926467
[TBL] [Abstract][Full Text] [Related]
12. Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs.
Green JL; Okerberg ES; Sejd J; Palafox M; Monserrat L; Alemayehu S; Wu J; Sykes M; Aban A; Serra V; Nomanbhoy T
Mol Cancer Ther; 2019 Apr; 18(4):771-779. PubMed ID: 30837298
[TBL] [Abstract][Full Text] [Related]
13. PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer.
Zhao B; Burgess K
Chem Commun (Camb); 2019 Feb; 55(18):2704-2707. PubMed ID: 30758029
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a novel covalent CDK4/6 inhibitor based on palbociclib scaffold.
Shan H; Ma X; Yan G; Luo M; Zhong X; Lan S; Yang J; Liu Y; Pu C; Tong Y; Li R
Eur J Med Chem; 2021 Jul; 219():113432. PubMed ID: 33857728
[TBL] [Abstract][Full Text] [Related]
15. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
16. CDK6 Inhibition: A Novel Approach in AML Management.
Uras IZ; Sexl V; Kollmann K
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260549
[TBL] [Abstract][Full Text] [Related]
17. Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma.
Bronner SM; Merrick KA; Murray J; Salphati L; Moffat JG; Pang J; Sneeringer CJ; Dompe N; Cyr P; Purkey H; Boenig GL; Li J; Kolesnikov A; Larouche-Gauthier R; Lai KW; Shen X; Aubert-Nicol S; Chen YC; Cheong J; Crawford JJ; Hafner M; Haghshenas P; Jakalian A; Leclerc JP; Lim NK; O'Brien T; Plise EG; Shalan H; Sturino C; Wai J; Xiao Y; Yin J; Zhao L; Gould S; Olivero A; Heffron TP
Bioorg Med Chem Lett; 2019 Aug; 29(16):2294-2301. PubMed ID: 31307887
[TBL] [Abstract][Full Text] [Related]
18. A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas.
Hadjadj D; Kim SJ; Denecker T; Ben Driss L; Cadoret JC; Maric C; Baldacci G; Fauchereau F
Aging (Albany NY); 2017 Dec; 9(12):2695-2716. PubMed ID: 29283884
[TBL] [Abstract][Full Text] [Related]
19. A Search for Cyclin-Dependent Kinase 4/6 Inhibitors by Pharmacophore-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulations.
Susanti NMP; Damayanti S; Kartasasmita RE; Tjahjono DH
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948218
[TBL] [Abstract][Full Text] [Related]
20. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
